

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1- 14 (Canceled).

15 (Original): A method of inhibiting stroke or multiinfarct dementia in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.

16 (Original): The method according to claim 15, wherein the rapamycin is rapamycin.

17 (Original): The method according to claim 15, wherein the rapamycin is a ester, ether, oxime, hydrazone, or hydroxylamine of rapamycin.

18 (Original): The method according to claim 17, wherein the rapamycin is a 42-ester or 42-ether of rapamycin.

19 (Original): The method according to claim 18, wherein the rapamycin is rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid.

20 (Original): The method according to claim 18, wherein the rapamycin is 42-O-(2-hydroxy)ethyl rapamycin.

21 (Original): The method according to claim 15, wherein the rapamycin is provided in combination with one or more agents selected from the groups consisting of an ACE inhibitor, an angiotensin II receptor antagonists, a fibric acid derivative, a

HMG Co-A reductase inhibitor, a beta adrenergic blocking agent, a calcium channel blocker, an antioxidant; an anticoagulants, or an agent useful in hormone replacement therapy containing an estrogen.

22 (Previously presented): A method of treating or inhibiting lipid deposition or accumulation in a vascular wall in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.

23 (Original): The method according to claim 22, wherein the rapamycin is rapamycin.

24 (Original): The method according to claim 22, wherein the rapamycin is a ester, ether, oxime, hydrazone, or hydroxylamine of rapamycin.

25 (Original): The method according to claim 24, wherein the rapamycin is a 42-ester or 42-ether of rapamycin.

26 (Original): The method according to claim 25, wherein the rapamycin is rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid.

27 (Original): The method according to claim 25, wherein the rapamycin is 42-O-(2-hydroxy)ethyl rapamycin.

28 (New): A method of inhibiting stroke or multiinfarct dementia in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin and one or more agents selected from a calcium channel blocker and an anticoagulant.

29 (New): A method of treating or inhibiting lipid deposition or accumulation in a vascular wall in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin and one or more agents selected from a calcium channel blocker and an anticoagulant.